Rintatolimod
As of the edition of 20 October 2026, Rintatolimod is a drug: stopped in 2026; acts on TLR3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Unknown
- Registered trials
- 26, 8 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Infections; Digestive system; Immune system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Rintatolimod.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TLR3 | Toll-like receptor 3 | O15455 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 18 | 5 | 4 | 8 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 26 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AIM ImmunoTech | Lead sponsor of trials | 2012 to now |
| Hem | Lead sponsor of trials |